Novonesis delivered 8% organic sales growth in the first nine months of 2025
Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards.
COPENHAGEN, Denmark – November 6, 2025. Novonesis delivered 8% organic sales growth in the first nine months of 2025. Full-year outlook is narrowed upwards to 7-8%, previously 6-8%.
Ester Baiget, President & CEO:
"I am pleased with our performance in the first nine months, where we delivered 8% organic sales growth with solid profitability. Our performance was strong across all sales areas and in emerging and developed markets. We delivered 37.3% adjusted EBITDA margin, despite significant currency headwinds, demonstrating the strength and resilience of our business model. Following a robust nine-months performance including favorable timing in the third quarter, we indicate mid-single-digit organic sales growth for the fourth quarter and lift the bottom end of the range now expecting 7-8% for the full year. We continue to execute on our strategic priorities, positioning us firmly to deliver on our 2030 targets."
Highlights of our 9M results:
- Strong broad-based organic sales growth of 8% (Q3: 6%), including the negative impact of exiting certain countries of ~1 percentage point (Q3: ~2 percentage points). Price contributed by ~1 percentage point (Q3: ~1 percentage point).
- Food & Health at 9% organic sales growth (Q3: 6%) including the negative impact of exiting certain countries of ~2 percentage points (Q3: ~5 percentage points). Planetary Health at 8% organic sales growth (Q3: 6%).
- Emerging Markets at 12% organic sales growth (Q3: 10%); Developed Markets at 6% organic sales growth (Q3: 4%).
- Adjusted EBITDA margin at 37.3% (Q3: 37.1%), up by 130 bps (Q3: down by 30 bps). including significant currency headwinds. Adjusted net profit increased by 22% (Q3: 19%).
- NIBD/EBITDA at 2.0x, and free cash flow before acquisitions at EUR 668.4 million (Q3: EUR 361.3 million).
2025 outlook: Organic sales growth is now expected between 7-8% (previously 6-8%) including an indication of mid-single-digit growth in Q4 following favorable timing in Q3. Excluding the exit from certain countries, organic sales growth for the year is expected at 8-9% (previously 7-9%). The adjusted EBITDA margin is expected at the lower end of the 37-38% range, including significant currency headwinds.
Media relations
Magnus Højberg Mernild
Senior Media Relation Manager
media-relations@novozymes.com
+45 51 71 78 30
Tobias Cornelius Bjorklund
Head of Investor Relations
tobb@novonesis.com
Attachment
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
